GHB has a reputation problem that works against its users. Because it’s often filed away as a club drug or a bodybuilding supplement, its withdrawal syndrome gets underestimated by nearly everyone, including some clinicians. That’s a dangerous mistake. GHB withdrawal is closer to severe alcohol or benzodiazepine withdrawal than to anything people picture when they hear the word “party drug,” and it can turn into delirium fast.
The short version: stopping GHB abruptly after regular use can produce agitation, psychosis, seizures, and a delirium that requires intensive medical management. It is not a withdrawal to attempt alone, and the window for it to escalate is measured in hours because of how quickly the drug leaves the body.
Key Takeaways
- GHB has a very short half-life so that withdrawal can begin within hours of a missed dose rather than the next day.
- Abrupt withdrawal without adequate treatment leads to delirium in more than half of cases.
- Regular users often dose around the clock, including overnight, which is a strong signal of physical dependence.
- Vital signs are unreliable for judging severity, so monitoring has to be clinical and continuous rather than based on a blood pressure reading.
- Supervised tapering, whether with pharmaceutical GHB or benzodiazepines, is the standard of care and takes days to weeks.
What GHB Does and Why Stopping Hurts
Gamma-hydroxybutyrate is a central nervous system depressant that occurs naturally in the body in tiny amounts. In the doses people take recreationally or to manage sleep and anxiety, it acts on GABA-B receptors and its own GHB receptors, producing sedation, euphoria, and relaxation. In pharmaceutical form, sodium oxybate is approved for narcolepsy, which tells you the compound has real neurological effects at controlled doses.
Outside of that narrow medical use, GHB is a Schedule I controlled substance. The Drug Enforcement Administration’s overview of GHB notes it circulates as a colorless, odorless liquid that’s difficult to detect, which is part of why dosing errors and dependence often go unnoticed until withdrawal forces the issue. Users frequently measure by capfuls rather than milligrams, so the gap between an effective dose and an overdose can be small and inconsistent between batches.
The problem is the half-life. GHB clears the body in roughly 30 to 60 minutes, which means blood levels crash quickly. People who develop dependence typically respond by dosing every two to four hours, day and night, setting alarms to redose before withdrawal symptoms wake them. That around-the-clock pattern is one of the clearest markers of dependence and one of the reasons withdrawal starts so abruptly.
With chronic use, the brain compensates for the constant depressant load. Take the drug away and the same rebound excitation seen in alcohol and benzodiazepine withdrawal takes over, but on a much faster clock.
The Withdrawal Timeline
GHB withdrawal moves faster than most people expect. A general pattern:
- 1 to 6 hours after the last dose: Anxiety, tremor, sweating, insomnia, and craving begin. This is often the point where a person redoses without recognizing it as withdrawal.
- 6 to 24 hours: Symptoms intensify. Tachycardia, hypertension, nausea, agitation, and confusion become prominent.
- 24 to 72 hours: The highest-risk window for psychosis, hallucinations, severe agitation, and delirium.
- Days 4 to 14: Acute symptoms gradually settle in treated patients, though insomnia, anxiety, and craving frequently persist.
A large study across seven Dutch addiction treatment centers followed 285 patients through a supervised pharmaceutical GHB taper and found the tapering phase lasted 11 days on average, with a recovery phase averaging another six days. That’s the timeline under good medical management, not the worst case.
What Withdrawal Actually Looks Like
The same research identified the symptoms patients reported most often. Subjectively, the leading complaints were craving, fatigue, insomnia, sweating, and feeling gloomy. On objective assessment, the most prevalent findings were craving, fatigue, tremors, sweating, and sudden cold or warm sensations.
Severe presentations add a different category of symptom:
- Visual and auditory hallucinations
- Paranoid thinking and delusions
- Severe agitation and combativeness
- Disorientation to time, place, and person
- Seizures
- Autonomic instability with dangerous swings in heart rate and blood pressure
The researchers noted something clinically important: they found no association between vital signs and subjective or objective withdrawal symptoms. In plain terms, a person’s blood pressure and pulse can look reasonable while their withdrawal is genuinely severe. Anyone trying to gauge safety by checking vitals at home is reading a gauge that doesn’t work for this drug.
Why Delirium Is the Central Risk
The single most quoted figure in the GHB literature is also the most sobering. Abrupt GHB withdrawal without adequate treatment leads to delirium in over 50% of cases. Compare that to alcohol, where roughly 3% to 5% of people in withdrawal progress to delirium tremens, and the difference in scale is obvious.
GHB withdrawal delirium tends to arrive with prominent psychosis, which creates a practical danger beyond the medical one. A person in this state may not understand they’re ill, may resist help, and may act on paranoid beliefs. Family members frequently describe someone who was lucid in the afternoon and unrecognizable by night. That trajectory is why hospital- or inpatient-level monitoring is recommended, not just suggested.
How Supervised Detox Manages It
Treatment focuses on replacing the depressant effect, then removing it slowly enough for the brain to readjust. Two approaches dominate.
Pharmaceutical GHB tapering. In the Dutch study, patients were started on roughly 70% of their reported self-administered illicit dose, then reduced by 300 mg per dose per day, with dosing typically every two to three hours. This mirrors the person’s existing dosing rhythm, which is why it controls symptoms so predictably.
Benzodiazepine tapering. High-dose benzodiazepines address the same GABA imbalance and are widely available in hospital settings. Some patients require substantial doses, and adjunct medications are sometimes added for breakthrough agitation or psychosis. Published cases describe baclofen used to manage GHB withdrawal, reflecting how often clinicians have to reach beyond a single medication when benzodiazepines alone don’t hold the symptoms.
The reason both approaches take days rather than hours is that the taper has to move slower than the drug’s own clearance. Reported cases of GHB withdrawal syndrome include patients whose symptoms re-emerged when the taper was cut short, which is why treatment teams generally extend rather than compress the schedule when a patient is still symptomatic.
Alongside medication, supervised care provides:
- Continuous observation, since severity can’t be judged from vital signs alone
- A quiet, low-stimulation environment that reduces agitation and disorientation
- Fluid, electrolyte, and nutritional correction
- Seizure precautions and rapid intervention if one occurs
- Assessment for other substances, since GHB is frequently used alongside alcohol or stimulants
- Treatment of the anxiety, depression, or insomnia that often drove the use in the first place
Choosing where that happens matters. The questions worth asking when evaluating a medical detox center include whether they have experience with sedative-hypnotic withdrawal specifically, not just opioids.
Why This Withdrawal Gets Missed
Several things conspire to delay proper care for GHB withdrawal:
- It doesn’t show on standard drug panels. Routine toxicology screens don’t detect GHB, and it clears the body so fast that even targeted testing has a narrow window.
- The presentation mimics psychiatric illness. A patient arriving agitated and paranoid can be treated as a first psychotic episode rather than a withdrawal emergency.
- Patients underreport. Many people describe GHB as a supplement or sleep aid rather than a drug, particularly when it was obtained as a wellness product.
- Clinicians see it rarely. Compared with alcohol and opioids, GHB dependence is uncommon enough that many providers have never managed a case.
Being direct about the amount used, the dosing interval, and the overnight schedule gives the treating team what it needs. That last detail, whether a person wakes at night to redose, is one of the most useful pieces of information a clinician can get.
A one-year case series following patients through GHB detoxification treatment and its complications concluded that withdrawal from GHB is a severe and potentially dangerous condition, with a higher prevalence of complications than most other drugs. That framing is worth holding onto, because it runs directly against the cultural assumption that GHB sits somewhere near alcohol on the risk scale. Clinically, it sits above it.
Polysubstance Use Raises the Stakes
GHB is rarely the only thing involved. Alcohol is a frequent companion, and the combination is particularly risky because both are central nervous system depressants with overlapping mechanisms. Withdrawal from both at once is more severe than either alone and needs a plan that accounts for both timelines.
Stimulants complicate the picture differently, masking sedation during use and leaving a heavier crash afterward. Benzodiazepines used to self-manage GHB withdrawal create a second dependence with its own taper requirements that can’t be rushed. Sorting out what’s actually in the system, and in what quantity, is the first job of an assessment.
All of this points to a simple conclusion. GHB withdrawal is one of the few syndromes where the medical literature and the lived experience agree: it is dangerous, it moves quickly, and it responds well to treatment when treatment starts early. The people who do badly are almost always the ones who tried to stop on their own, redosed to escape symptoms, and eventually crashed into a delirium they couldn’t recognize was happening.
References
- GHB Drug – U.S. Drug Enforcement Administration
- Characterization of the GHB Withdrawal Syndrome – National Library of Medicine
- Successful management of GHB withdrawal using baclofen as a standalone therapy – National Library of Medicine
- Gamma-hydroxybutyrate withdrawal syndrome: a case report – National Library of Medicine
- Course and complications of GHB detoxification treatment: a 1-year case series – PubMed, National Library of Medicine
FAQs
Can GHB Withdrawal Kill You?
Yes. Deaths have been reported from complications including status epilepticus, autonomic instability, and injuries sustained during delirium. The risk drops dramatically with medical supervision, which is why you should not attempt it alone.
How Is GHB Withdrawal Different From Alcohol Withdrawal?
The mechanisms overlap, but GHB moves faster and produces delirium far more often. Alcohol withdrawal typically starts within 6 to 24 hours, while GHB can start within a few hours of a missed dose. Delirium rates are also much higher with untreated GHB withdrawal.
Will GHB Show Up on a Drug Test?
Not on standard panels. GHB requires specialized testing and clears the body within hours, so a negative screen tells you very little. Diagnosis relies mostly on history, which is why being straightforward with the clinical team matters.
What If Someone Refuses Help During Withdrawal?
Withdrawal delirium impairs insight, so refusal is often a symptom rather than a decision. If a person is disoriented, hallucinating, or a danger to themselves, call 911. Florida’s Marchman Act also provides a legal pathway for families to seek involuntary assessment and stabilization for someone with a substance use disorder.
How Long Until Sleep Returns to Normal?
Insomnia is one of the most persistent GHB withdrawal symptoms. It can last weeks after the acute phase ends, particularly for people who originally started using it as a sleep aid. Treating the underlying sleep problem without reintroducing a depressant is an important part of aftercare.
